Drugs targeting STAT3 may represent a promising therapeutic option against this cancer [9,15,16], even if several other oncogenic pathways contribute to driving lymphoma cell survival, including PI3K/AKT/mTOR, NFkB, ERK1/2 and mevalonate [17,18,19,20,21]. This evidence concerns the gene NFKB1 and cancer.